Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Vivani Medical ( (VANI) ).
On May 13, 2026, Vivani Medical reported first-quarter 2026 results, highlighting progress toward launching SLIM-1, a Phase 1 trial of its NPM-139 semaglutide implant for chronic weight management in Australia, expected to begin mid-2026 with top-line data anticipated by year-end. The company is simultaneously advancing a next-generation NPM-139 configuration designed for higher semaglutide doses and planning an IND submission to support a Phase 2 dose-ranging study in 2027, underscoring its strategic push into long-acting obesity treatments.
Vivani ended the quarter with $28 million in cash, cash equivalents, restricted cash and capital commitments, supported by $30.2 million in gross capital raises over the past year, and expects this liquidity to fund operations through the first half of 2027 despite a net loss of $6.8 million. Management is also evaluating paths to separate its neuromodulation business by transitioning Cortigent into an independent, publicly traded company, signaling an effort to unlock value in its neurotechnology assets while sharpening Vivani’s focus on metabolic implants.
The most recent analyst rating on (VANI) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, large recurring losses, and significant cash burn with rising leverage). Technicals are a partial offset with price above key moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add pullback risk. Valuation remains challenged due to the negative P/E and lack of dividend support.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants based on its proprietary NanoPortal technology, aimed at delivering near constant-rate dosing of medicines for chronic diseases. The company is building a portfolio of GLP-1–based implants targeting metabolic conditions such as obesity and type 2 diabetes, seeking to address widespread medication non-adherence associated with daily pills and weekly injections.
Cortigent, Inc., Vivani’s wholly owned subsidiary, focuses on neuromodulation devices that use precision neurostimulation to help patients regain critical functions, such as vision and limb movement. Its Orion cortical stimulation system, which has FDA Breakthrough Device designation, completed a six-year Early Feasibility Study in 2025 targeting blindness from common causes, while the platform is also being adapted to aid stroke patients with arm and hand paralysis.
Average Trading Volume: 249,089
Technical Sentiment Signal: Strong Sell
Current Market Cap: $96.5M
See more insights into VANI stock on TipRanks’ Stock Analysis page.